lobbying_activities: 3386178
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3386178 | 397ee196-8bc1-4817-a774-c81f97ffe7cd | Q2 | EMERGENT BIOSOLUTIONS INC. | 304931 | EMERGENT BIOSOLUTIONS INC | 2025 | second_quarter | DIS | - Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act - Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 - Opioid crisis legislation, naloxone access and awareness - State opioid response (SOR) Grant funding FY25 and FY26 - Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 - Tribal Opioid Response Grant funding for FY26 - NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone - H.R.1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 440000 | 0 | 0 | 2025-07-16T16:02:09-04:00 |